Search Bar & Filters
Found 82 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the safety and effectiveness of the Ankura II AAA, AE, and large-size IE Stent Graft Systems for treating infrarenal abdominal aortic aneurysms AAA in patients suitable for endovascular intervention. The study focuses on those with localized bulging of the abdominal aorta, a condition that can lead to serious complications if untreated. This clinical investigation aims to evaluate major adverse events within 30 days after the procedure and the success rate of treatment at 12 months. Participants will undergo endovascular aneurysm repair EVAR, a minimally invasive procedure where a covered stent graft is placed inside the aneurysm through the femoral artery to redirect blood flow and reduce pressure on the weakened aortic wall. The Ankura II system includes various stent grafts and delivery devices tailored to patient anatomy, with some larger sizes for specific cases. The procedure is guided by fluoroscopy and aims to isolate the diseased aortic segment while maintaining blood flow. During the study, participants will have assessments including monitoring for major and device-related adverse events, mortality, aneurysm enlargement, endoleak blood leakage around the graft, stent migration or occlusion, and need for additional interventions. These will be evaluated at multiple time points up to five years post-operation. Follow-up visits will involve imaging, clinical evaluations, and safety monitoring to determine treatment success and long-term outcomes.
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating IM-101 in adults with generalized myasthenia gravis gMG and ocular myasthenia gravis oMG, focusing on those with acetylcholine receptor AChR antibody-positive and AChR antibody-negative forms. The goal is to assess the safety, tolerability, how the drug moves through and affects the body, and the potential effectiveness of IM-101. This Phase 1b2 trial is sponsored by ImmunAbs Inc. and includes multiple study parts to explore these aspects thoroughly. Participants will receive IM-101 or a placebo through intravenous infusions. In Part A, participants get a loading dose on Day 1 and Day 15, followed by a maintenance dose on Day 29, with doses escalating across cohorts. In Part B, dosing includes loading doses on Day 1 and Day 15 and maintenance doses on Days 29, 57, and 85. Some may receive additional doses depending on decisions by an independent data monitoring committee. The study uses randomized, double-blind assignments to compare different dose levels and placebo effects. During the study, participants will be monitored for side effects and safety up to about 99 days in Part A and 169 days in Part B. Researchers will assess the impact of treatment on daily living activities and specific myasthenia gravis severity scores at baseline and Week 16. Safety assessments include tracking adverse events, serious adverse events, and events leading to discontinuation. Participants will undergo regular evaluations to measure the pharmacokinetics and pharmacodynamics of IM-101, with follow-up visits scheduled according to the dosing timeline.
Actively Recruiting
Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
1-10 of 82
1